The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass

Anesthesia and Analgesia

Volumn 103, Issue 1, 2006, Pages 2-8

  Maslow, Andrew D ^a,b   Stearns, Gary ^a   Batula, Parag ^a   Schwartz, Carl S ^a   Gough, Jeffrey ^b   Singh, Arun K ^a  

^a RHODE ISLAND HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; GUANYLATE CYCLASE; GUANYLATE CYCLASE INHIBITOR; HYPERTENSIVE AGENT; LACTIC ACID; LISINOPRIL; METHYLENE BLUE; NITRIC OXIDE; NORADRENALIN; PHENYLEPHRINE; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART SURGERY; HEMODYNAMICS; HUMAN; HYPOTENSION; INFLAMMATION; LACTATE BLOOD LEVEL; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE; TISSUE PERFUSION;

EID: 33745865227     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000221261.25310.fe     Document Type: Article

References (39)

1. Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. Thorac Cardiovasc Surg 1998; 116:973-80.
2. Johnson MR. Low systemic vascular resistance after cardiopulmonary bypass: are we any closer to understanding the enigma? Crit Care Med 1999; 27:1048-50.
3. Cugno M, Nussberger J, Biglioli P, et al. Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion. Chest 2001; 120:1776-82.
4. Conti VR, McQuitty C. Vasodilation and cardiopulmonary bypass: the role of bradykinin and the pulmonary vascular endothelium (editorial). Chest 2001; 120:1759-61.
5. Hill GE, Whitten CW, Landers DF. The influence of cardiopulmonary bypass on cytokines and cell-cell communication. J Cardiothorac Vasc Anesth 1997; 11:367-75.
6. Hill GE. Cardiopulmonary bypass-induced inflammation: Is it important? J Cardiothorac Vasc Anesth 1998; 12:21-5.
7. Herskowitz A, Mangano DT. Inflammatory cascade: A final common pathway for perioperative injury. (editorial) Anesthesiology 1996; 85:957-60.
8. Royston D. The inflammatory response and extracorporeal circulation. J Cardiothorac Vasc Anesth 1997; 11:341-54.
9. Dagenais F, Mathieu P. Rescue therapy with methylene blue in systemic inflammatory response syndrome after cardiac surgery. Can J Card 2003; 19:167-9.
10. Leyh RG, Kofidis T, Struber M, et al. Methylene blue: The drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J Thorac Cardiovasc Surg 2003; 125:1426-31.
11. Koelzow H, Gedney JA, Baumann J, et al. The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. Anesth Analg 2002; 94:824-9.
12. Grayling M, Deakin CD. Methylene blue during cardiopulmonary bypass to treat refractory hypotension in septic endocarditis. J Thorac Cardiovasc Surg 2003; 125:426-7.
13. Yiu P, Robin J, Pattison CW. Reversal of refractory hypotension with single-dose methylene blue after coronary artery bypass surgery. J Thorac Cardiovasc Surg 1999; 118:195-6.
14. Ozal E, Kuralay E, Yildirim V, et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg 2005; 79:1615-9.
15. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004; 77:496-9.
16. Tuman KJ, McCarthy RJ, O'Connor et al. Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirement after cardiopulmonary bypass. Anesth Analg 1995; 80:473-9.
17. Pigott DW, Nagle C, Allman K. Effect of omitting regular ACE inhibitor medication before cardiac surgery on haemodynamic variables and vasoactive drug requirements. Br J Anaesth 1999; 83:715-20.
18. Singh AK, Feng WC, Bert AA, et al. Warm body, cold heart surgery: clinical experience in 2817 patients. Eur J Cardiothoracic Surg 1993; 7:225-30.
19. Bert AA, Stearns GT, Feng W, Singh AK. Normothermic cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11:91-9.
20. Kirov MY, Evgenov O, Evgenov NV, et al. Infusion of methylene blue in human septic shock: A pilot, randomized, controlled study. Crit Care Med 2001; 29:1860-7.
21. O'Dwyer C, Woodson LC, Conroy BP, et al. Regional perfusion abnormalities with phenylephrine during normothermic bypass. Ann Thorac Surg 1997; 63:728-35.
22. Levi RC, Alloatti G, Penna C, Gallo MP. Guanylate-cyclase-mediated inhibition of cardiac ICa by carbachol and sodium nitroprusside. Eur J Phys 1994; 426:419-26.
23. Naim KL, Rabindranauth P, Weiss HR, et al. Positive inotropy due to lowering cyclic GMP is also mediated by increases in cyclic AMP in control and hypertrophic hearts. Can J Phys & Pharm 1998; 76:605-12.
24. Gauthier C, Leblais V, Kobzik L, et al. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 1998; 102:1377-84.
25. Leone RJ Jr., Weiss HR, Scholz PM. Positive functional effects of milrinone and methylene blue are not additive in control and hypertrophic canine hearts. J Surg Res 1998; 77:23-8.
26. Flesch M, Kilter H, Cremers B, et al. Acute effects of nitric oxide and cyclic GMP on human myocardial contractility. J Pharm & Exp Ther 1997; 281:1340-9.
27. Kinugawa KI, Kohmoto O, Yao A, et al. Cardiac inducible nitric oxide synthase negatively modulates myocardial function in cultured rat myocytes. Am J Phys 1997; 272:H35-47.
28. Woolley G, Staszewska-Woolley J. A role for cyclic GMP in the initiation of cardiac pressor reflexes by bradykinin and capsaicin. Pol J Pharm & Pharm 1990; 42:249-57.
29. Abi-Gerges N, Eschenhagen T, Hove-Madsen L. Methylene blue is a muscarinic antagonist in cardiac myocytes. Mol Pharm 1997; 52:482-90.
30. Baydoun AR, Peers SH, Cirino G, Woodward B. Vasodilator action of endothelin-1 in the perfused rat heart. J Cardiovasc Pharm 1990; 15:759-63.
31. Brown NJ, Gainer JV, Stein CM, et al. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999; 33:1431-5.
32. Talbot MP, Tremblay I, Denault AY, et al. Vasopressin for refractory hypotension during cardiopulmonary bypass. Thorac Cardiovasc Surg 2000; 120:401-2.
33. Kristof AS, Magder S. Low systemic vascular resistance state in patients undergoing cardiopulmonary bypass. Crit Care Med 1999; 27:11211-7.
34. Christakis GT, Fremes SE, Koch J-P, et al. Determinants of low systemic vascular resistance during cardiopulmonary bypass. Ann Thorac Surg 1994; 58:1040-9.
35. Mekontso-Dessap A, Houel R, Soustelle C. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg 2001; 71:1428-32.
36. Tsai BM, Wang M, Turrentine MW, et al. Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: basic mechanisms to potential therapies. Ann Thorac Surg 2004; 78:360-8.
37. Maxey TS, Smith CD, Kern JA, et al. Beneficial effects of inhaled nitric oxide in adult cardiac surgical patients. Ann Thorac Surg 2002; 73:529-33.
38. Fortier S, DeMaria RG, Lamarche Y, et al. Inhaled prostacyclin reduces cardiopulmonary bypass-induced pulmonary endothelial dysfunction via increased cyclic adenosine monophosphate levels. J Thorac Cardiovasc Surg 2004; 128:109-16.
39. Fischer LG, Aken HV, Burkle H. Management of pulmonary hypertension: physiologic and pharmacologic considerations for anesthesiologists. Anesth Analg 2003; 96:1603-16.